分期全主动脉弓置换联合开窗分支腔内修复治疗巨主动脉综合征
本研究回顾了11例巨主动脉综合征患者接受分期全主动脉弓置换(TAR)联合开窗分支腔内修复(F-BEVAR)的临床结局。TAR后30天死亡1例(9.0%),F-BEVAR后无死亡;2年患者生存率80%±9%,无主动脉相关死亡,4例需再次介入。分期策略在高危患者中可行,但需更大样本和更长随访。
要点
- 分期TAR联合F-BEVAR治疗巨主动脉综合征在高危患者中可行。
- TAR后30天死亡1例(9.0%),F-BEVAR后无死亡。
- 2年生存率80%±9%,无主动脉相关死亡,4例再次介入。
核心结论
- 分期TAR联合F-BEVAR治疗巨主动脉综合征是选定高危患者的可行替代方案。
- 需要更大临床经验和更长随访来验证。
研究设计与样本
- 回顾性研究,纳入2014年1月至2018年12月连续11例(8男;平均年龄71±7岁)巨主动脉综合征患者。
- F-BEVAR在前瞻性、非随机、医生发起的IDE协议下进行。
- 巨主动脉综合征定义为升主动脉、主动脉弓及I-II型胸腹主动脉瘤。
主要发现
- 6例为Stanford A型夹层修复后慢性夹层动脉瘤,5例为退行性动脉瘤且主动脉弓无合适锚定区。
- 胸腹主动脉瘤I型4例,II型7例。
- TAR后30天死亡1例(9.0%),TAR后主要不良事件3例(27%),包括1例脊髓损伤。
- F-BEVAR后主要不良事件2例(20%),包括1例因脑脊液引流导致脊髓血肿的脊髓损伤。
- 平均随访14±10个月,术后2年患者生存率80%±9%,主要通畅率94%±6%,次要通畅率100%,免于肾-肠系膜靶血管不稳定86%±8%。
关键数值与推荐
- TAR与F-BEVAR平均间隔245±138天,期间无动脉瘤破裂。
- 平均住院时间12±6天。
- 随访期间无主动脉相关死亡,4例再次介入均采用腔内方式。
临床怎么用
- 对于无合适锚定区的高危巨主动脉综合征患者,可考虑分期TAR联合F-BEVAR。
- 需注意脊髓损伤风险,包括脑脊液引流相关并发症。
- 术后需密切随访,监测靶血管不稳定和再次介入需求。
局限性
- 样本量小(11例),随访时间短(平均14±10个月)。
- 回顾性设计,非随机对照。
- 单中心经验,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the present study was to review the clinical outcomes of a staged approach using total arch replacement (TAR) with an elephant trunk or a frozen elephant trunk, followed by fenestrated-branched endovascular aortic repair (F-BEVAR) for patients with mega aortic syndrome. METHODS: We reviewed the clinical data and outcomes of 11 consecutive patients (8 men; mean age, 71 ± 7 years) treated by staged TAR and F-BEVAR from January 2014 to December 2018. The F-BEVAR procedures were performed under a prospective, nonrandomized, physician-sponsored investigational device exemption protocol. All patients had had mega aortic syndrome, defined by an ascending aorta, arch, and extent I-II thoracoabdominal aortic aneurysm. The endpoints were 30-day mortality, major adverse events (MAE), patient survival, freedom from reintervention, and freedom from target vessel instability. RESULTS: Of the 11 patients, 6 had developed chronic postdissection aneurysms after previous Stanford A (three A11, two A10, one A9) dissection repair and 5 had had degenerative aneurysms with no suitable landing zone in the aortic arch. The thoracoabdominal aortic aneurysms were classified as extent I in four patients and extent II in seven. One patient had died within 30 days after TAR (9.0%). However, none of the remaining 10 patients who had undergone F-BEVAR had died. First-stage TAR resulted in MAE in three patients (27%), including one spinal cord injury. The mean length of stay was 12 ± 6 days. The mean interval between TAR and F-BEVAR was 245 ± 138 days with no aneurysm rupture during the interval. Second-stage F-BEVAR was associated with MAE in two patients (20%), including spinal cord injury in one patient from spinal hematoma due to placement of a cerebrospinal fluid drain. The mean follow-up period was 14 ± 10 months. At 2 years postoperatively, patient survival, primary patency, secondary patency, and freedom from renal-mesenteric target vessel instability was 80% ± 9%, 94% ± 6%, 100%, and 86% ± 8%, respectively. No aortic-related deaths occurred during the follow-up period. Four patients had required reintervention, all performed using an endovascular approach. CONCLUSIONS: A staged approach to treatment of mega aortic syndrome using TAR and F-BEVAR is a feasible alternative for selected high-risk patients. Larger clinical experience and longer follow-up are needed.
引用
- Kawajiri H, Tenorio ER, Khasawneh MA, et al. Staged total arch replacement, followed by fenestrated-branched endovascular aortic repair, for patients with mega aortic syndrome. J Vasc Surg. 2020. PMID: 33189762. doi:10.1016/j.jvs.2020.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。